EGFR and gastric cancer: Indeed, several phase II clinical trials demonstrated a benefit of combining chemotherapy and anti-EGFR therapy in GC patients (18–20); however, randomized, open-label phase III trials failed to show a clinical benefit for anti-EGFR therapy in GC treatment (21, 22).